BETHESDA, Md., July 22,
2024 /PRNewswire/ -- Precision Biologics, Inc.
("Precision"), a clinical-stage immunotherapy and targeted oncology
company, announced today that on July
16, 2024, the USPTO granted another patent for its lead
clinical asset, NEO-201, which is currently being tested in Phase 2
human Clinical Trials in the US.
NEO-201 is a humanized IgG1 monoclonal antibody with multiple
mechanisms of action. It has been shown previously to kill cancer
cells expressing its target (truncated Core 1 O-glycans) which is
expressed in numerous cancers; however, it does not bind to most
normal tissues. In addition, NEO-201 binds to immune suppressor
cells, including regulatory T cells (Treg cells) and granulocytic
myeloid-derived suppressor cells (gMDSCs), which are thought to
diminish the efficacy of cancer immunotherapy.
The patent granted by USPTO on July 16,
2024 (Patent No. US 12,037,410B2) describes the ability of
NEO-201 to bind to Treg cells, and its use in targeting Treg cells.
NEO-201 may be used for isolation and detection of Treg cells. In
addition, the patent claims that NEO-201 can mediate the killing of
Treg cells through complement mediated cytotoxicity (CDC) in vitro.
Therapeutic methods and combination therapies using NEO-201 in
combination with another anti-cancer agent are also described in
the patent.
According to claims of the patent, in the Phase I clinical
trial, using NEO-201 as single agent for the treatment of subjects
with advanced solid tumors which have progressed on or not
responded to standard treatments, NEO-201 was proven to bind and
reduce the amount of circulating Tregs in subjects with stable
disease after treatment.
This finding supported the rationale of the ongoing phase II
clinical trial evaluating the activity of NEO-201 with
pembrolizumab (Keytruda) in adults with solid tumors resistant to
prior checkpoint inhibitors. This trial is currently enrolling
patients with metastatic Non-Small Cell Lung Cancer (NSCLC), Head
and Neck Cancer, Endometrial Cancer and Cervical Cancer, whose
disease has previously progressed through prior checkpoint
inhibitor therapy (including prior Keytruda).
(https://clinicaltrials.gov/ct2/show/NCT03476681)
This ongoing Phase 2 trial is testing to see if combining
NEO-201 with Keytruda can reactivate the effectiveness of
checkpoint inhibitors when they no longer work.
Data from the ongoing Phase 2 trial was recently presented on
June 1st, 2024, at ASCO
Annual Meeting 2024, at the Mc Cormick Convention Center,
Chicago, Illinois, USA. This data
demonstrated that NEO-201 reduces the quantity of
regulatory T cells and gMDSCs in peripheral blood mononuclear cells
(PBMCs) of cancer patients and this reduction is associated with
durable stabilization of disease. (click here).
In addition, a recent study, performed by Drs. Atsushi Tanaka and Shimon Sakaguchi from Osaka University, Japan, independently analyzed by flow
cytometry the ability of NEO-201 to recognize Treg cells in from
PBMCs from healthy donors, confirming findings from Precision
Biologics in PBMCs from cancer patients. This study was presented
as poster at the Association for Cancer Research
(AACR) Annual Meeting 2024 on April 8th, 2024. Here there is the link to the
poster: https://lnkd.in/dJaaAjij
About Precision Biologics
Founded in 2012, Precision Biologics, Inc. is a clinical stage
biotechnology corporation focused on developing therapeutic and
diagnostic products for the detection and treatment of cancer. The
company's antibody drug candidates and diagnostics are designed to
detect and target the tumor with minimal damage to healthy cells.
Precision Biologics is uniquely positioned to create innovative
therapeutics through the use of proprietary cancer vaccines,
several of which have demonstrated success in human trials. By
marrying this platform with today's breakthrough technologies, the
company is developing antibody therapeutics that could change the
way we detect and treat cancer. For more information on Precision
Biologics, please
visit http://www.precision-biologics.com/.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/precision-biologics-announces-the-united-states-patent-and-trademark-office-uspto-has-granted-a-patent-for-its-lead-monoclonal-antibody-neo-201-for-methods-and-compositions-for-targeting-treg-cells-302202053.html
SOURCE Precision Biologics